ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Exclusion criteria

• . Previous or concurrent cancer that is distinct from GCT in primary site or histology, EXCEPT treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1). Any cancer curatively treated equal to or greater than 3 years prior to enrollment is permitted.
• . History of cardiac disease:
• . Active clinically serious infection(s) defined as equal to or greater than Grade 2 according to NCI CTCAE, version 4.0.
• . Known metastatic brain or meningeal tumors, unless the subject is greater than 6 months from definitive therapy, has a negative imaging study within 4 weeks of first dose of study drug and is clinically stable (no concomitant therapy, including supportive therapy with steroids or anticonvulsant medications) with respect to the tumor at the time of first dose of study drug.
• . Any primary CNS GCT.
• . Concurrent treatment with anticancer therapies including cytotoxic chemotherapy, immunotherapy, radiotherapy, vaccines or investigational therapy during the study or within 3 weeks of first dose of study drug.
• . Any major surgical procedure within 3 weeks prior to first dose of study drug.
• . Prior therapy with c-MET inhibitors, including ARQ197.